Aloe Therapeutics

Executive Summary

Aloe Therapeutics is a privately-held biotechnology company pioneering a novel cancer immunotherapy approach using allogeneic cell therapy. Its lead candidate, AIM-001, leverages the immune response from transplant rejection to activate the immune system against solid tumors. The therapy is administered locally during biopsy or tumor resection, aiming to sensitize tumors to checkpoint immunotherapies. This differentiated mechanism addresses the challenge of 'cold' tumors that are resistant to existing immunotherapies. Founded in 2018 and headquartered in San Diego, Aloe is in the early stages of development with no disclosed funding or valuation. The company's focus on a unique combination of transplant immunology and cell therapy positions it in a niche but potentially high-impact area of oncology. With its allogeneic approach, AIM-001 offers the possibility of an off-the-shelf therapy that could be combined with standard checkpoint inhibitors to improve outcomes in solid tumors. Despite limited public information, the innovative strategy warrants attention as the company advances toward clinical development.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for AIM-00160% success
• Q2 2027Series A Financing Round50% success
• Q3 2026Preclinical Efficacy Data Publication70% success